November 30, 2018 – Clinical diagnostics intelligence platform company MaxQ AI and Samsung NeuroLogica announced a distribution agreement to integrate MaxQ’s artificial intelligence (AI) software with Samsung NeuroLogica’s medical imaging hardware in the United States and European Union acute care marketplace. As part of this agreement, Samsung NeuroLogica will be able enhance its offerings with MaxQ’s Accipio Ix, part of MaxQ’s Accipio Insight intracranial hemorrhage platform, which supports acute care physicians by identifying patients with suspected intracranial hemorrhage, and prioritizing those patients using adult non-contrast head computed tomography (CT) imaging.
MaxQ AI Senior Vice President Commercial Operations Chris Schnee said that coupling the Accipio Insight platform with Samsung Neurologica’s mobile CT offering will bring critical life-saving decisions directly to patients in mobile stroke units and to the bed-side of acute care hospital departments.
Accipio Ix recently received both U.S. Food and Drug Administration (FDA) and European CE Mark approval. Samsung NeuroLogica’s U.S. and EU sales teams will now offer Accipio Ix solution as an additional tool for its OmniTom mobile 16-slice CT scanner. The OmniTom delivers high-quality non-contrast CT scans at the patient’s bedside with omni-directional wheels. In addition, MaxQ’s AI solutions will be available for integration into Samsung NeuroLogica’s U.S. and EU mobile stroke units (MSU), a specialized ambulance or other emergency vehicle that is equipped with a CereTom CT (computed tomography) scanner. The mobile unit with diagnostic CT imaging capabilities is designed to allow the team onboard to quickly assess whether a patient is having a stroke caused by hemorrhage.
Watch the VIDEO: Creating and Operating a Mobile Stroke Unit
A stroke occurs when blood flow to the brain is interrupted by a blockage or a rupture in an artery, depriving brain tissue of oxygen. Stroke is the fifth leading cause of death in the United States and a leading cause of disability. According to the Centers for Disease Control (CDC), close to 800,000 Americans suffer a stroke each year. Treatment can be delayed after a suspected stroke patient arrives in the emergency department because of the time needed to determine the best treatment pathway.
Accipio Ix leverages artificial intelligence technology to automatically analyze non-contrast head CT images. The AI-powered platform is designed to be highly sensitive to the presence of ICH, identifying and prioritizing patients with a brain bleed for the treating physician. It provides a capability for rapid escalation and prioritization of the patient and can be natively integrated into CT and picture archiving and communication systems (PACS) using the imaging industry standard DICOM, installed both on-premise and cloud-capable.
MaxQ demonstrated Accipio Ix – along with additional Accipio platform solutions in development – during the Radiological Society of North America (RSNA) 2018 Annual Meeting, Nov. 25-30 in Chicago.
For more information: www.maxq.ai, www.neurologica.com
March 26, 2026 
